AstraZeneca PLC (AZN) annual results, year to 31 December 2018: revenue USD 22,090 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2018 it reported revenue of USD 22,090 million, down 1.7% on the year before. Its profit attributable to shareholders was USD 2,155 million, down 28.2%, and diluted earnings per share USD 1.70.
The year to 31 December 2018, against the year before
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Revenue | 22,465 | 22,090 |
| Cost of sales | 4,318 | 4,936 |
| Gross profit | 18,147 | 17,154 |
| Research and development | 5,757 | 5,932 |
| Selling, general and administrative | 10,233 | 10,031 |
| Operating profit | 3,677 | 3,387 |
| Finance costs | 1,508 | 1,419 |
| Profit before tax | 2,227 | 1,993 |
| Income tax | -641 | -57.0 |
| Profit for the year | 2,868 | 2,050 |
| Profit attributable to shareholders | 3,001 | 2,155 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Cash from operations | 3,578 | 2,618 |
| Purchase of property, plant and equipment | 1,326 | 1,043 |
| Free cash flow | 2,252 | 1,575 |
| Dividends paid | 3,519 | 3,484 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Total assets | 63,354 | 60,651 |
| Equity attributable to shareholders | 14,960 | 12,468 |
| Cash and cash equivalents | 3,324 | 4,831 |
| Borrowings, as filed | 17,807 | 19,113 |
| Trade and other receivables | 5,009 | 5,574 |
| Inventories | 3,035 | 2,890 |
| Goodwill | 11,825 | 11,707 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2017 | Dec 2018 |
|---|---|---|
| Gross margin | 80.8% | 77.7% |
| Operating margin | 16.4% | 15.3% |
| Net margin | 13.4% | 9.8% |
| Free cash flow margin | 10.0% | 7.1% |
| Return on year-end equity | 20.1% | 17.3% |
| Effective tax rate | -28.8% | -2.9% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018, this page
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2018, filed 16 February 2021, accession 0001104659-21-022456: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.